Neurocrine Biosciences, Inc. announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO), effective June 2, 2025. Dr. Keswani will lead the clinical development and medical affairs activities at Neurocrine.
Dr. Keswani is an accomplished physician-scientist with over 20 years of pharmaceutical industry experience, possessing broad R&D expertise across multiple therapeutic areas. He succeeds Eiry W. Roberts, M.D., who served as CMO for seven years and will transition to a strategic advisory role within Neurocrine.
This leadership change is expected to bring new perspectives and drive the company's ambitious pipeline forward. Dr. Keswani's extensive experience is anticipated to be instrumental in advancing Neurocrine's mission to develop life-changing treatments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.